Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Emergency and Critical Care

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

All‐cause mortality D60 or more

It is very uncertain whether canakinumab changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.55 [0.16, 1.91]
1 study · 45 participants
Very low

All‐cause mortality D60 or more

It is very uncertain whether anakinra changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 1.03 [0.68, 1.56]
4 studies · 1633 participants
Very low